MTD
Mettler Toledo
$1,164.07
▲ 1.7%Updated Today 7:15 PM ET
▼ Down 0.1% over the last 12 months
Market Cap
$23.13B
P/E
26.6x
Forward P/E (est.)
25.01x
ROE
1675.8%
Revenue Growth
6.8%
EPS Growth
6.3%
Profit Margin
21.4%
FCF Yield
3.9%
Debt / Equity
81.23x
ROIC
—
Interest Coverage
—
Current Ratio
1.2x
Dividend Yield
—
Implied Growth (rev. DCF)
5.1%
Rating Score
52/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what MTD's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. MTD trades near $1,164.07, below its 50-day average ($1,199.40) and 200-day average ($1,315.96). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 42 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. MTD's is $30.56 (~2.6% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month MTD found buyers near $1,027.65 (support) and sellers near $1,198.02 (resistance); its 52-week range is $1,023.05–$1,525.17. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.7× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Mettler Toledo (MTD) is a large-cap company in the Life Sciences Tools & Services industry, part of the Health Care sector of the S&P 500, with a market value around $23.13B.
In its latest reported year it generated about $4.03B in revenue and $869.19M in net profit.
Our model rates MTD Neutral (52/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
2.0%
Revenue moved from $3.72B in 2021 to $4.03B in 2025, a 2.0% compound annual growth rate. The most recent year grew a steady 6.8% year over year. Slower, mature growth is common for established businesses.
Gross Margin
59.4%
Operating Margin
25.8%
Net Margin
21.6%
ROE
1675.8%
Mettler Toledo keeps about 21.4% of each sales dollar as net profit, with a 59.4% gross margin and 25.8% operating margin. Return on equity is 1675.8%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$2.09B
Net Debt
$2.02B
Net Debt / EBITDA
—
Debt / Equity
81.23x
Leverage: debt-to-equity is 81.2x, with a current ratio of 1.2x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $2.09B of total debt against $69.06M of cash.
Operating CF
$955.77M
Free Cash Flow
$848.65M
FCF Margin
21.1%
In the latest year Mettler Toledo produced about $955.77M of operating cash flow and $848.65M of free cash flow after capital spending. That is a free-cash-flow yield of about 3.9% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
26.6x
P/S
5.81x
P/B
—
EV / EBITDA
—
MTD trades at 26.6x trailing earnings (about 25.0x on estimated forward earnings), 5.8x sales. Reverse-engineering today's price implies the market expects roughly 5.1% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How MTD stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), MTD ranks #30 of 59 by our overall rating. It trades at roughly in line versus the sector on earnings (26.6x P/E vs. 25.4x median) with a higher return on equity (1675.8% vs. 14.9%) and slower revenue growth (6.8% vs. 7.9%).
P/E vs sector
26.6x
median 25.4x
ROE vs sector
1675.8%
median 14.9%
Growth vs sector
6.8%
median 7.9%
Sector rank
#30
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$983.70 – $1,660.00
vs. $1,164.07 today · expected CAGR -3% – 7%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $4.31B | $4.61B | $4.93B | $5.28B | $5.65B |
| Net income | $947.81M | $1.01B | $1.09B | $1.16B | $1.24B |
| EPS | $46.90 | $50.19 | $53.70 | $57.46 | $61.48 |
| Share price (low) | $750.46 | $802.99 | $859.20 | $919.35 | $983.70 |
| Share price (high) | $1,266.40 | $1,355.05 | $1,449.91 | $1,551.40 | $1,660.00 |
| CAGR (low–high) | -36% / 9% | -17% / 8% | -10% / 8% | -6% / 7% | -3% / 7% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for MTD:
- High net margins (21.4%) point to pricing power or efficiency.
- Strong return on equity (1675.8%) shows capital is put to work well.
The case against MTD:
- Elevated leverage (debt/equity 81.2x) adds financial risk.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Balance-sheet risk — debt/equity of 81.2x magnifies the impact of higher rates or weaker earnings.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Mettler Toledo is a large-cap health care business growing at a mature pace, with solid profitability, and a heavier debt load to watch. It trades at 26.6x earnings, which our model scores Neutral (52/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.